tirzepatide and aspirin Medications Safety Information

Broader market trends such as the global obesity epidemic, cardiometabolic care focus, and patient preference for high-efficacy therapies strongly support tirzepatides growth trajectory

Clinical trial enrollment only

hydration and unproven supplements do not meaningfully alter clearance rates

In addition, UnitedHealth Group said its medical loss ratio for the quarter was 82.3%, compared to 81.6%

Affordability improvements may expand coverage: Frdric Leblanc, a pharmacist at iA Financial, notes that insurers are "preparing for everything we need to do so that everybody benefits from a lower price, both in diabetes and eventually in weight management." Sandoz CEO Richard Saynor has described Canada as the world's second-largest GLP-1 market